February 2017 Analysis

Industry Trend Analysis - Psoriasis Indication Will Reinforce Cimzia's Worth To UCB - FEB 2017

In seeking to expand the number of conditions Cimzia is indicated for, UCB is following a well-trodden path in the autoimmune sphere. A successful indication for psoriasis would prove to be highly beneficial. The condition affects nearly 3% of the world's population, or around 125mn. Cimzia is already a cornerstone drug for UCB, but with key patents for Cimzia expiring in 2024, UCB will be keen...

READ FULL ARTICLE